02318nas a2200421   4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653001100111653002800122653002100150653002400171653003000195653001100225653001100236653002300247653001200270653000900282653001600291653001500307653001600322100001600338700001600354700001500370700001300385700001400398700001700412245010700429856004600536300001100582490000700593050001800600520126400618022001401882       2013                            d  c2013 May10aAdolescent10aAdult10aAged10aAged, 80 and over10aBrazil10aCross-Sectional Studies10aDisabled Persons10aDisease Progression10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aPrevalence10aYoung Adult1 aMonteiro LD1 aAlencar CHM1 aBarbosa JC1 aBraga KP1 aCastro MD1 aHeukelbach J00a[Physical disabilities in leprosy patients after discharge from multidrug therapy in Northern Brazil].  uhttp://www.scielo.br/pdf/csp/v29n5/09.pdf  a909-200 v29  aMONTEIRO 20133 a<p>Chronic sequelae and disabilities are one of the main problems in leprosy. The current study aimed to estimate the prevalence of disabilities in leprosy patients after successfully completing multidrug therapy in Araguaína, Tocantins State, Brazil. This was a cross-sectional study including 282 cases diagnosed from 2004 to 2009. The degrees of disability at diagnosis and at discharge from treatment were collected from medical records and the National Information System for Notifiable Diseases (SINAN). A simplified neurological workup was performed after discharge from treatment. The prevalence of disabilities at diagnosis was 29.4%, and 8.9% of then was grade II. Between diagnosis and discharge, the degree of physical disability worsened in 25% of cases. At diagnosis, the proportion of deformities was significantly higher in men (RR = 1.7; 95%CI: 1.23-2.37). There was a significant association between disability and multibacillary disease (p < 0.001) and occurrence of reactions (p < 0.001). The data show that after discharge from multidrug therapy, in order to prevent chronic sequelae and functional limitations, continuous monitoring is still needed for individuals that have been recorded as cured and thus deleted from the records.</p>  a1678-4464